ALK and non-small cell lung carcinoma: Drugs for cancers that are resistant to prior therapies include ceritinib (indication: ALK-positive non-small cell lung cancer (NSCLC) resistant to crizotinib) [25] and ponatinib hydrochloride (indication: chronic myelogenous leukaemia resistant to prior therapy).